Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling
Keyword(s):
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. e17509-e17509
◽
Keyword(s):
2021 ◽
pp. 135581962110354